Genomic signatures of breast cancer metastasis

Cytogenetic and Genome Research

Volumn 118, Issue 2-4, 2007, Pages 116-129

  Urquidi, V ^a   Goodison, S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYSTEINE RICH PROTEIN 61;

BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CHROMOSOME MUTATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE MODEL; GENE EXPRESSION; GENE IDENTIFICATION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; DISEASE MODELS, ANIMAL; GENOMICS; HUMANS; KARYOTYPING; NEOPLASM METASTASIS; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 36248931070     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108292     Document Type: Review

References (126)

1. Abdelrahim M, Smith R 3rd, Burghardt R, Safe S: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64:6740-6749 (2004).
2. Adeyinka A, Kytola S, Mertens F, Pandis N, Larsson C: Spectral karyotyping and chromosome banding studies of primary breast carcinomas and their lymph node metastases. Int J Mol Med 5:235-240 (2000).
3. Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V: Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation 71:114-125 (2003).
4. Albertson DG: Profiling breast cancer by array CGH. Breast Cancer Res Treat 78:289-298 (2003).
5. Aubele M, Auer G, Braselmann H, Nahrig J, Zitzelsberger H, et al: Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal Cell Pathol 24:77-87 (2002).
6. Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, et al: Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2:351-356 (2005).
7. Barlund M, Tirkkonen M, Forozan F, Tanner MM, Kallioniemi O, Kallioniemi A: Increased copy number at 17q22→q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer 20:372-376 (1997).
8. Bartholin L, Wessner LL, Chirgwin JM, Guise TA: The human CYR61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett 246:230-236 (2007).
9. Bastian BC, Wesselmann U, Pinkel D, Leboit PE: Molecular cytogenetic analysis of spitz nevi shows clear differences to melanoma. J Invest Dermatol 113:1065-1069 (1999).
10. Beisner J, Buck MB, Fritz P, Dippon J, Schwab M, et al: A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer. Cancer Res 66:7554-7561 (2006).
11. Bieche I, Lidereau R: Genetic alterations in breast cancer. Genes Chromosomes Cancer 14:227-251 (1995).
12. Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer 1:46-54 (2001).
13. Blegen H, Will JS, Ghadimi BM, Nash HP, Zetterberg A, et al: DNA amplifications and aneuploidy, high proliferative activity and impaired cell cycle control characterize breast carcinomas with poor prognosis. Anal Cell Pathol 25:103-114 (2003).
14. Bourguignon LY, Zhu H, Shao L, Chen YW: Ankyrin-tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J Cell Biol 150:177-191 (2000).
15. Brandenberger R, Schmidt A, Linton J, Wang D, Backus C, et al: Identification and characterization of a novel extracellular matrix protein nephronectin that is associated with integrin alpha8beta1 in the embryonic kidney. J Cell Biol 154:447-458 (2001).
16. Brenton JD, Carey LA, Ahmed AA, Caldas C: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 23:7350-7360 (2005).
17. Brigstock DR: The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 20:189-206 (1999).
18. Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, et al: Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res 6:R601-607 (2004).
19. Chambers AF, Naumov GN, Vantyghem SA, Tuck AB: Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res 2:400-407 (2000).
20. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, et al: Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2:E7 (2004).
21. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102:3738-3743 (2005).
22. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, et al: Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 12:3950-3960 (2006).
23. Dai H, van 't Veer L, Lamb J, He YD, Mao M, et al: A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65:4059-4066 (2005).
24. Devilee P, Cornelisse CJ: Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1198:113-130 (1994).
25. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR: Mappfinder: Using gene ontology and genmapp to create a global gene-expression profile from microarray data. Genome Biol 4:R7 (2003).
26. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, et al: Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 3:1-13 (2005).
27. Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893-895 (1977).
28. Fritz G, Kaina B: Rho GTPases: Promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 6:1-14 (2006).
29. Fritz G, Just I, Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682-687 (1999).
30. Goodison S, Kawai K, Hihara J, Jiang P, Yang M, et al: Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 9:3808-3814 (2003).
31. Goodison S, Viars C, Urquidi V: Molecular cytogenetic analysis of a human breast metastasis model: Identification of phenotype-specific chromosomal rearrangements. Cancer Genet Cytogenet 156:37-48 (2005a).
32. Goodison S, Yuan J, Sloan D, Kim R, Li C, et al: The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 65:6042-6053 (2005b).
33. Han W, Han MR, Kang JJ, Bae JY, Lee JH, et al: Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 6:92 (2006).
34. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, et al: Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 100:2532-2537 (2003).
35. Hu Z, Fan C, Oh DS, Marron JS, He X, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96 (2006).
36. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, et al: Gene expression predictors of breast cancer outcomes. Lancet 361:1590-1596 (2003).
37. Hurst J, Maniar N, Tombarkiewicz J, Lucas F, Roberson C, et al: A novel model of a metastatic human breast tumour xenograft line. Br J Cancer 68:274-276 (1993).
38. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, et al: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 62:6240-6245 (2002).
39. Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, et al: Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 147:905-911 (1995).
40. Janssen EA, Baak JP, Guervos MA, van Diest PJ, Jiwa M, Hermsen MA: In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 201:555-561 (2003).
41. Jennings R, Alsarraj M, Wright KL, Munoz-Antonia T: Regulation of the human transforming growth factor beta type II receptor gene promoter by novel Sp1 sites. Oncogene 20:6899-6909 (2001).
42. Ji C, Casinghino S, McCarthy TL, Centrella M: Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-beta type I receptor. J Biol Chem 272:21260-21267 (1997).
43. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE: Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 11:781-791 (2004).
44. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, et al: Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91:2156-2160 (1994).
45. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al: From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res 34:D354-357 (2006).
46. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549 (2003).
47. Kauraniemi P, Barlund M, Monni O, Kallioniemi A: New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 61:8235-8240 (2001).
48. Kawai K, Viars C, Arden K, Tarin D, Urquidi V, Goodison S: Comprehensive karyotyping of the HT-29 colon adenocarcinoma cell line. Genes Chromosomes Cancer 34:1-8 (2002).
49. Kluger HM, Chelouche Lev D, Kluger Y, McCarthy MM, Kiriakova G, et al: Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res 65:5578-5587 (2005).
50. Knutsen T, Gobu V, Knaus R, Padilla-Nash H, Augustus M, et al: The interactive online SKY/m-FISH & CGH database and the Entrez cancer chromosomes search database: Linkage of chromosomal aberrations with the genome sequence. Genes Chromosomes Cancer 44:52-64 (2005).
51. Kreunin P, Urquidi V, Lubman DM, Goodison S: Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 4:2754-2765 (2004).
52. Kristensen VN, Sorlie T, Geisler J, Langerod A, Yoshimura N, et al: Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: Clinical implications. Clin Cancer Res 11:878s-883s (2005).
53. Kytola S, Rummukainen J, Nordgren A, Karhu R, Farnebo F, et al: Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer 28:308-317 (2000).
54. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 12:84-89 (2005).
55. Lau LF, Lam SC: The CCN family of angiogenic regulators: The integrin connection. Exp Cell Res 248:44-57 (1999).
56. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, et al: A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17:163-170 (1999).
57. Lev DC, Kiriakova G, Price JE: Selection of more aggressive variants of the gi101a human breast cancer cell line: A model for analyzing the metastatic phenotype of breast cancer. Clin Exp Metastasis 20:515-523 (2003).
58. Li S, Huang S, Peng SB: Overexpression of G protein-coupled receptors in cancer cells: Involvement in tumor progression. Int J Oncol 27:1329-1339 (2005).
59. Liang Z, Wu T, Lou H, Yu X, Taichman RS, et al: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64:4302-4308 (2004).
60. Loi S, Desmedt C, Cardoso F, Piccart M, Sotiriou C: Breast cancer gene expression profiling: Clinical trial and practice implications. Pharmacogenomics 6:49-58 (2005).
61. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, et al: Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100:5974-5979 (2003).
62. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616 (2004).
63. Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, et al: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22:2680-2688 (2003).
64. Macville M, Veldman T, Padilla-Nash H, Wangsa D, O'Brien P, et al: Spectral karyotyping, a 24-colour FISH technique for the identification of chromosomal rearrangements. Histochem Cell Biol 108:299-305 (1997).
65. McGuire WL: Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 10:5-9 (1987).
66. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al: Genes that mediate breast cancer metastasis to lung. Nature 436:518-524 (2005).
67. Morimura N, Tezuka Y, Watanabe N, Yasuda M, Miyatani S, et al: Molecular cloning of POEM: A novel adhesion molecule that interacts with alpha8beta1 integrin. J Biol Chem 276:42172-42181 (2001).
68. Morris JS, Carter NP, Ferguson-Smith MA, Edwards PA: Cytogenetic analysis of three breast carcinoma cell lines using reverse chromosome painting. Genes Chromosomes Cancer 20:120-139 (1997).
69. Muller A, Homey B, Soto H, Ge N, Catron D, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56 (2001).
70. Nicolini A, Carpi A, Tarro G: Biomolecular markers of breast cancer. Front Biosci 11:1818-1843 (2006).
71. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, et al: Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: Identification of genes associated with progression and metastasis. Int J Oncol 25:797-819 (2004).
72. Nishizaki T, DeVries S, Chew K, Goodson WH 3rd, Ljung BM, et al: Genetic alterations in primary breast cancers and their metastases: Direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer 19:267-272 (1997).
73. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335-348 (2005).
74. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72 (1996).
75. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. Breast Cancer Res 7:R953-964 (2005).
76. Perbal B: CCN proteins: Multifunctional signalling regulators. Lancet 363:62-64 (2004).
77. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, et al: Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8:R23 (2006).
78. Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, et al: Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 101:8431-8436 (2004).
79. Popescu NC, Zimonjic DB: Chromosome and gene alterations in breast cancer as markers for diagnosis and prognosis as well as pathogenetic targets for therapy. Am J Med Genet 115:142-149 (2002).
80. Price JE, Polyzos A, Zhang RD, Daniels LM: Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50:717-721 (1990).
81. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54 (2003).
82. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101:9309-9314 (2004).
83. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM: Mining for regulatory programs in the cancer transcriptome. Nat Genet 37:579-583 (2005).
84. Ried T, Just KE, Holtgreve-Grez H, du Manoir S, Speicher MR, et al: Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 55:5415-5423 (1995).
85. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, et al: Histological grading of breast carcinomas: A study of interobserver agreement. Hum Pathol 26:873-879 (1995).
86. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, et al: Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of Sp-1. J Biol Chem 271:28220-28228 (1996).
87. Safe S, Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 41:2438-2448 (2005).
88. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, et al: The role of CXCR4 receptor expression in breast cancer: A large tissue microarray study. Breast Cancer Res Treat 97:275-283 (2006).
89. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, et al: Multicolor spectral karyotyping of human chromosomes. Science 273:494-497 (1996).
90. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, et al: Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66:5278-5286 (2006).
91. Segal E, Friedman N, Kaminski N, Regev A, Koller D: From signatures to models: Understanding cancer using microarrays. Nat Genet 37 Suppl:S38-45 (2005).
92. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D: The relationship of BRMS1 and RHOGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 18:519-525 (2000).
93. Shadeo A, Lam WL: Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res 8:R9 (2006).
94. Shen R, Ghosh D, Chinnaiyan AM: Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. BMC Genomics 5:94 (2004).
95. Shevde LA, Welch DR: Metastasis suppressor pathways - an evolving paradigm. Cancer Lett 198:1-20 (2003).
96. Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, et al: Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 21:1045-1059 (2006).
97. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, et al: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64:8604-8612 (2004).
98. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, et al: The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2:116-123 (2000).
99. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874 (2001).
100. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423 (2003).
101. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, et al: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: Gene expression analyses across three different platforms. BMC Genomics 7:127 (2006).
102. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272 (2006).
103. Speicher MR, Gwyn Ballard S, Ward DC: Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 12:368-375 (1996).
104. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2:573-583 (2002).
105. Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman L, et al: In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci USA 101:615-620 (2004).
106. Sugino T, Yamaguchi T, Ogura G, Saito A, Hashimoto T, et al: Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers. BMC Med 2:9 (2004).
107. Sun Y, Goodison S, Li J, Liu L, Farmerie W: Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics 23:30-37 (2007).
108. Tanner MM, Tirkkonen M, Kallioniemi A, Isola J, Kuukasjarvi T, et al: Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 56:3441-3445 (1996).
109. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP: Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21:177-184 (1998).
110. Tuma RS: A big trial for a new technology: Trans-BIG project takes microarrays into clinical trials. J Natl Cancer Inst 96:648-649 (2004).
111. Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, et al: Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8:61-74 (2002).
112. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536 (2002).
113. van de Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AA, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009 (2002).
114. Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM: cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 96:17-39 (2006).
115. von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, et al: String: Known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res 33:D433-437 (2005).
116. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679 (2005).
117. Wang-Rodriguez J, Urquidi V, Rivard A, Goodison S: Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res 5:R136-143 (2003).
118. Watson MB, Bahia H, Ashman JN, Berrieman HK, Drew P, et al: Chromosomal alterations in breast cancer revealed by multicolour fluorescence in situ hybridization. Int J Oncol 25:277-283 (2004).
119. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van 't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100:15901-15905 (2003).
120. Weigelt B, Hu Z, He X, Livasy C, Carey LA, et al: Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65:9155-9158 (2005a).
121. Weigelt B, Wessels LF, Bosma AJ, Glas AM, Nuyten DS, et al: No common denominator for breast cancer lymph node metastasis. Br J Cancer 93:924-932 (2005b).
122. Wong CM, Lee JM, Ching YP, Jin DY, Ng IO: Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 63:7646-7651 (2003).
123. Xie D, Jauch A, Miller CW, Bartram CR, Koeffler HP: Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex fish and comparative genomic hybridization. Int J Oncol 21:499-507 (2002).
124. Yang F, Foekens JA, Yu J, Sieuwerts AM, Timmermans M, et al: Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. Oncogene 25:1413-1419 (2006).
125. Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, et al: Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 66:4065-4078 (2006).
126. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, et al: Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 60:1546-1551 (2000).